Journal of Neuro-Oncology

, Volume 138, Issue 1, pp 173–182 | Cite as

Solitary-fibrous tumor/hemangiopericytoma of the central nervous system: a population-based study

  • Connor J. Kinslow
  • Samuel S. Bruce
  • Ali I. Rae
  • Sameer A. Sheth
  • Guy M. McKhann
  • Michael B. Sisti
  • Jeffrey N. Bruce
  • Adam M. Sonabend
  • Tony J. C. Wang
Clinical Study


The World Health Organization (WHO) classification of tumors of the central nervous system (CNS) was recently updated, restructuring solitary fibrous tumor (SFT) and hemangiopericytoma (HPC) into one combined entity. This is the first population-based study to examine outcomes of SFT/HPC based on the new WHO guidelines. The Surveillance, Epidemiology, and End Results (SEER) database (1998–2013) was queried to examine age-adjusted incidence and prognostic factors associated with overall survival in 416 surgically resected cases. Age-adjusted incidence was calculated to be 3.77 per 10,000,000 and was rising. Median survival was 155 months, with 5- and 10-year survival rates of 78 and 61%, respectively. Younger age, Asian/Pacific Islander versus white race, benign histology, tumor location, gross-total resection (GTR), and GTR plus radiation (RT) versus subtotal resection were significantly associated with survival. In multivariable analysis, older age (HR = 1.038, p < 0.0001), infratentorial location (HR = 2.019, p = 0.038), GTR (HR = 0.313, p = 0.041), and GTR + RT (HR = 0.215, p = 0.008) were independent prognostic factors. In the HPC and borderline/malignant subgroups, GTR + RT was associated with significantly increased survival compared with GTR alone (HR = 0.537, p = 0.039 and HR = 0.525, p = 0.038). After eliminating patients that died within 3 months of diagnosis, GTR + RT was still associated with an incremental increase in survival (HR = 0.238, p = 0.031) over GTR alone (HR = 0.280, p = 0.054). GTR + RT may be optimal in the management CNS HPC and SFT/HPC tumors with borderline/malignant features. This study, in combination with existing literature, warrants further investigation of adjuvant radiation through a prospective clinical trial.


Solitary-fibrous tumor Hemangiopericytoma Central nervous system Meningeal tumor Gross-total resection Radiation therapy 



We would like to thank the developers of the Surveillance, Epidemiology, and End Results program.

Compliance with ethical standards

Conflict of interest

Tony J. C. Wang reports personal fees and nonfinancial support from AbbVie, nonfinancial support from Merck, personal fees from AstraZeneca, personal fees from Doximity, nonfinancial support from Novocure, personal fees and nonfinancial support from Elekta and personal fees from Wolters Kluwer, outside the submitted work. All other authors report no financial conflicts of interest.

Supplementary material

11060_2018_2787_MOESM1_ESM.docx (440 kb)
Supplementary material 1 (DOCX 440 KB)


  1. 1.
    Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. CrossRefPubMedGoogle Scholar
  2. 2.
    Robinson DR, Wu Y-M, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sung Y-S, Chen C-L, Zhang L, Wang R, Su F, Iyer MK, Roychowdhury S, Siddiqui J, Pienta KJ, Kunju LP, Talpaz M, Mosquera JM, Singer S, Schuetze SM, Antonescu CR, Chinnaiyan AM (2013) Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet 45: 180–185.
  3. 3.
    Chmielecki J, Crago AM, Rosenberg M, O’Connor R, Walker SR, Ambrogio L, Auclair D, McKenna A, Heinrich MC, Frank DA, Meyerson M (2013) Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet 45: 131–132.
  4. 4.
    Schweizer L, Koelsche C, Sahm F, Piro RM, Capper D, Reuss DE, Pusch S, Habel A, Meyer J, Göck T, Jones DTW, Mawrin C, Schittenhelm J, Becker A, Heim S, Simon M, Herold-Mende C, Mechtersheimer G, Paulus W, König R, Wiestler OD, Pfister SM, von Deimling A (2013) Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol 125:651–658. CrossRefPubMedGoogle Scholar
  5. 5.
    Bouvier C, Metellus P, de Paula AM, Vasiljevic A, Jouvet A, Guyotat J, Mokhtari K, Varlet P, Dufour H, Figarella-Branger D (2012) Solitary fibrous tumors and hemangiopericytomas of the meninges: overlapping pathological features and common prognostic factors suggest the same spectrum of tumors. Brain Pathol (Zurich) 22:511–521. CrossRefGoogle Scholar
  6. 6.
    Macagno N, Figarella-Branger D, Mokthari K, Metellus P, Jouvet A, Vasiljevic A, Loundou A, Bouvier C (2016) Differential diagnosis of meningeal SFT-HPC and meningioma: which immunohistochemical markers should be used? Am J Surg Pathol 40:270–278. PubMedGoogle Scholar
  7. 7.
    Fritchie KJ, Jin L, Rubin BP, Burger PC, Jenkins SM, Barthelmess S, Moskalev EA, Haller F, Oliveira AM, Giannini C (2016) NAB2-STAT6 gene fusion in meningeal hemangiopericytoma and solitary fibrous tumor. J Neuropathol Exp Neurol 75:263–271. CrossRefPubMedGoogle Scholar
  8. 8.
    Savary C, Rousselet MC, Michalak S, Fournier HD, Taris M, Loussouarn D, Rousseau A (2016) [Solitary fibrous tumors and hemangiopericytomas of the meninges: Immunophenotype and histoprognosis in a series of 17 cases]. Ann Pathol 36:258–267. CrossRefPubMedGoogle Scholar
  9. 9.
    Fletcher CDM (2006) The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology 48:3–12. CrossRefPubMedGoogle Scholar
  10. 10.
    Yalcin CE, Tihan T (2016) Solitary fibrous tumor/hemangiopericytoma dichotomy revisited: a restless family of neoplasms in the CNS. Adv Anat Pathol 23:104–111. CrossRefPubMedGoogle Scholar
  11. 11.
    Bisceglia M, Galliani C, Giannatempo G, Lauriola W, Bianco M, D’Angelo V, Pizzolitto S, Vita G, Pasquinelli G, Magro G, Dor DB (2011) Solitary fibrous tumor of the central nervous system: a 15-year literature survey of 220 cases (August 1996–July 2011). Adv Anat Pathol 18:356–392. CrossRefPubMedGoogle Scholar
  12. 12.
    Zeng L, Wang Y, Wang Y, Han L, Niu H, Zhang M, Ke C, Chen J, Lei T (2016) Analyses of prognosis-related factors of intracranial solitary fibrous tumors and hemangiopericytomas help understand the relationship between the two sorts of tumors. J Neuro-Oncol. Google Scholar
  13. 13.
    Tihan T, Viglione M, Rosenblum MK, Olivi A, Burger PC (2003) Solitary fibrous tumors in the central nervous system. A clinicopathologic review of 18 cases and comparison to meningeal hemangiopericytomas. Arch Pathol Lab Med 127:432–439.;2 PubMedGoogle Scholar
  14. 14.
    Mena H, Ribas JL, Pezeshkpour GH, Cowan DN, Parisi JE (1991) Hemangiopericytoma of the central nervous system: a review of 94 cases. Hum Pathol 22:84–91CrossRefPubMedGoogle Scholar
  15. 15.
    Kinslow CJ, Rajpara RS, Wu C-C, Bruce SS, Canoll PD, Wang S-H, Sonabend AM, Sheth SA, McKhann GM, Sisti MB, Bruce JN, Wang TJC (2017) Invasiveness is associated with metastasis and decreased survival in hemangiopericytoma of the central nervous system. J Neuro-Oncol. Google Scholar
  16. 16.
    Guthrie BL, Ebersold MJ, Scheithauer BW, Shaw EG (1989) Meningeal hemangiopericytoma: histopathological features, treatment, and long-term follow-up of 44 cases. Neurosurgery 25:514–522CrossRefPubMedGoogle Scholar
  17. 17.
    Rutkowski MJ, Jian BJ, Bloch O, Chen C, Sughrue ME, Tihan T, Barani IJ, Berger MS, McDermott MW, Parsa AT (2012) Intracranial hemangiopericytoma: clinical experience and treatment considerations in a modern series of 40 adult patients. Cancer 118:1628–1636. CrossRefPubMedGoogle Scholar
  18. 18.
    Rutkowski MJ, Bloch O, Jian BJ, Chen C, Sughrue ME, Tihan T, Barani IJ, Berger MS, McDermott MW, Parsa AT (2011) Management of recurrent intracranial hemangiopericytoma. J Clin Neurosci 18:1500–1504. CrossRefPubMedGoogle Scholar
  19. 19.
    Ambrosini-Spaltro A, Eusebi V (2010) Meningeal hemangiopericytomas and hemangiopericytoma/solitary fibrous tumors of extracranial soft tissues: a comparison. Virchows Archiv Int J Pathol 456:343–354. CrossRefGoogle Scholar
  20. 20.
    Mathieu D (2016) Why do hemangiopericytomas have such high recurrence rates? Expert Rev Anticancer Ther 16:1095–1096. CrossRefPubMedGoogle Scholar
  21. 21.
    Bastin KT, Mehta MP (1992) Meningeal hemangiopericytoma: defining the role for radiation therapy. J Neurooncol 14:277–287CrossRefPubMedGoogle Scholar
  22. 22.
    Schiariti M, Goetz P, El-Maghraby H, Tailor J, Kitchen N (2011) Hemangiopericytoma: long-term outcome revisited. J Neurosurg 114:747–755. CrossRefPubMedGoogle Scholar
  23. 23.
    Ghose A, Guha G, Kundu R, Tew J, Chaudhary R (2014) CNS hemangiopericytoma: a systematic review of 523 patients. Am J Clin Oncol. Google Scholar
  24. 24.
    Carneiro SS, Scheithauer BW, Nascimento AG, Hirose T, Davis DH (1996) Solitary fibrous tumor of the meninges: a lesion distinct from fibrous meningioma. A clinicopathologic and immunohistochemical study. Am J Clin Oncol 106:217–224Google Scholar
  25. 25.
    Stout AP, Murray MR (1942) Hemangiopericytoma: a vascular tumor featuring Zimmermann’s pericytes. Ann Surg 116:26–33CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Kleihues P, Burger PC, Scheithauer BW (1993) The new WHO classification of brain tumours. Brain Pathol (Zurich) 3:255–268CrossRefGoogle Scholar
  27. 27.
    Greenlee RT, Goodman MT, Lynch CF, Platz CE, Havener LA, Howe HL (2010) The occurrence of rare cancers in United States adults, 1995–2004. Public Health Rep 125: 28–43 (Washington, DC: 1974)CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Bilimoria KY, Stewart AK, Winchester DP, Ko CY (2008) The national cancer data base: A powerful initiative to improve cancer care in the United States. Ann Surg Oncol 15:683–690. CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Warren JL, Harlan LC (2003) Can cancer registry data be used to study cancer treatment? Med Care 41:1003–1005. CrossRefPubMedGoogle Scholar
  30. 30.
    (released April 2016, based on the November 2015 submission) Surveillance, Epidemiology,and End Results (SEER) Program ( SEER*Stat Database: Incidence- SEER 9 Regs Research Data, Nov 2015 Sub (1973–2013) < Katrina/Rita Population Adjustment>- Linked To County Attributes - Total U.S., 1969–2014 Counties.
  31. 31.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109. CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Ghia AJ, Allen PK, Mahajan A, Penas-Prado M, McCutcheon IE, Brown PD (2013) Intracranial hemangiopericytoma and the role of radiation therapy: a population based analysis. Neurosurgery 72:203–209. CrossRefPubMedGoogle Scholar
  33. 33.
    Sonabend AM, Zacharia BE, Goldstein H, Bruce SS, Hershman D, Neugut AI, Bruce JN (2014) The role for adjuvant radiotherapy in the treatment of hemangiopericytoma: a Surveillance, Epidemiology, and End Results analysis. J Neurosurg 120:300–308. CrossRefPubMedGoogle Scholar
  34. 34.
    Stessin AM, Sison C, Nieto J, Raifu M, Li B (2013) The role of postoperative radiation therapy in the treatment of meningeal hemangiopericytoma—Experience from the SEER database. Int J Radiat Oncol Biol Phys 85:784–790. CrossRefPubMedGoogle Scholar
  35. 35.
    Noone AM, Lund JL, Mariotto A, Cronin K, McNeel T, Deapen D, Warren JL (2016) Comparison of SEER treatment data with medicare claims. Med Care 54:e55–e64. CrossRefGoogle Scholar
  36. 36.
    Rutkowski MJ, Sughrue ME, Kane AJ, Aranda D, Mills SA, Barani IJ, Parsa AT (2010) Predictors of mortality following treatment of intracranial hemangiopericytoma. J Neurosurg 113:333–339. CrossRefPubMedGoogle Scholar
  37. 37.
    Soyuer S, Chang EL, Selek U, McCutcheon IE, Maor MH (2004) Intracranial meningeal hemangiopericytoma: the role of radiotherapy. Cancer 100:1491–1497. CrossRefPubMedGoogle Scholar
  38. 38.
    Ramakrishna R, Rostomily R, Sekhar L, Rockhill J, Ferreira M (2014) Hemangiopericytoma: radical resection remains the cornerstone of therapy. J Clin Neurosci 21:612–615. CrossRefPubMedGoogle Scholar
  39. 39.
    Kim JH, Jung HW, Kim YS, Kim CJ, Hwang SK, Paek SH, Kim DG, Kwun BD (2003) Meningeal hemangiopericytomas: long-term outcome and biological behavior. Surg Neurol 59:47–53 (discussion 53–44)CrossRefPubMedGoogle Scholar
  40. 40.
    Lee EJ, Kim JH, Park ES, Khang SK, Cho YH, Hong SH, Kim CJ (2016) The impact of postoperative radiation therapy on patterns of failure and survival improvement in patients with intracranial hemangiopericytoma. J Neuro-Oncol 127:181–190. CrossRefGoogle Scholar
  41. 41.
    Chen L-f, Yang Y, Yu X-g, Gui Q-p, Xu B-n, Zhou D-b (2015) Multimodal treatment and management strategies for intracranial hemangiopericytoma. J Clin Neurosci 22:718–725. CrossRefPubMedGoogle Scholar
  42. 42.
    Choi J, Park S-H, Khang SK, Suh Y-L, Kim SP, Lee YS, Kwon HS, Kang S-G, Kim SH (2016) Hemangiopericytomas in the central nervous system: a Multicenter Study of Korean Cases with validation of the usage of STAT6 immunohistochemistry for diagnosis of disease. Ann Surg Oncol. Google Scholar
  43. 43.
    Zhang GJ, Wu Z, Zhang LW, Li D, Zhang JT (2017) Surgical management and adverse factors for recurrence and long-term survival in hemangiopericytoma patients. World Neurosurg. Google Scholar
  44. 44.
    Staples JJ, Robinson RA, Wen BC, Hussey DH (1990) Hemangiopericytoma—The role of radiotherapy. Int J Radiat Oncol Biol Phys 19:445–451. CrossRefPubMedGoogle Scholar
  45. 45.
    Ghia AJ, Chang EL, Allen PK, Mahajan A, Penas-Prado M, McCutcheon IE, Brown PD (2013) Intracranial hemangiopericytoma: patterns of failure and the role of radiation therapy. Neurosurgery 73:624–630. (discussion 630–621)CrossRefPubMedGoogle Scholar
  46. 46.
    Zhu H, Duran D, Hua L, Tang H, Chen H, Zhong P, Zheng K, Wang Y, Che X, Bao W, Wang Y, Xie Q, Gong Y (2016) Prognostic factors in patients with primary hemangiopericytomas of the central nervous system: a series of 103 cases at a single institution. World Neurosurg 90:414–419. CrossRefPubMedGoogle Scholar
  47. 47.
    Dufour H, Metellus P, Fuentes S, Murracciole X, Regis J, Figarella-Branger D, Grisoli F (2001) Meningeal hemangiopericytoma: a retrospective study of 21 patients with special review of postoperative external radiotherapy. Neurosurgery 48:756–762 (discussion 762–753)PubMedGoogle Scholar
  48. 48.
    Caldarella A, Crocetti E, Paci E (2011) Is the incidence of brain tumors really increasing? A population-based analysis from a cancer registry. J Neuro-Oncol 104:589–594. CrossRefGoogle Scholar
  49. 49.
    Suissa S (2008) Immortal time bias in pharmacoepidemiology. Am J Epidemiol 167:492–499. CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Connor J. Kinslow
    • 1
  • Samuel S. Bruce
    • 2
  • Ali I. Rae
    • 2
  • Sameer A. Sheth
    • 2
    • 3
  • Guy M. McKhann
    • 2
    • 3
  • Michael B. Sisti
    • 2
    • 3
  • Jeffrey N. Bruce
    • 2
    • 3
  • Adam M. Sonabend
    • 4
  • Tony J. C. Wang
    • 1
    • 3
  1. 1.Department of Radiation OncologyColumbia University Medical CenterNew YorkUSA
  2. 2.Department of Neurological SurgeryColumbia University Medical CenterNew YorkUSA
  3. 3.Herbert Irving Comprehensive Cancer CenterColumbia University Medical CenterNew YorkUSA
  4. 4.Department of Neurological SurgeryNorthwestern University Feinberg School of MedicineChicagoUSA

Personalised recommendations